SiBone (NASDAQ:SIBN) SVP Michael Pisetsky Sells 3,460 Shares

SiBone (NASDAQ:SIBN) SVP Michael Pisetsky sold 3,460 shares of the business’s stock in a transaction dated Friday, January 2nd. The shares were sold at an average price of $19.62, for a total value of $67,885.20. Following the completion of the transaction, the senior vice president owned 228,436 shares in the company, valued at $4,481,914.32. This trade represents a 1.49% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

SiBone Price Performance

Shares of NASDAQ:SIBN opened at $20.40 on Wednesday. The company has a quick ratio of 6.62, a current ratio of 7.97 and a debt-to-equity ratio of 0.21. SiBone has a 52 week low of $12.49 and a 52 week high of $21.07. The company has a 50-day moving average price of $18.58 and a 200 day moving average price of $17.04. The company has a market cap of $885.16 million, a P/E ratio of -40.00 and a beta of 0.69.

SiBone (NASDAQ:SIBN) last issued its earnings results on Monday, November 10th. The company reported ($0.11) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.16) by $0.05. The company had revenue of $48.66 million during the quarter, compared to analysts’ expectations of $46.67 million. SiBone had a negative net margin of 11.24% and a negative return on equity of 12.86%. Research analysts predict that SiBone will post -0.78 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of research firms have weighed in on SIBN. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of SiBone in a research note on Monday, December 29th. Morgan Stanley lifted their target price on SiBone from $20.00 to $23.00 and gave the company an “overweight” rating in a report on Tuesday, December 2nd. Truist Financial upped their price target on SiBone from $21.00 to $23.00 and gave the stock a “buy” rating in a research note on Thursday, December 18th. Canaccord Genuity Group lifted their price objective on SiBone from $26.00 to $27.00 and gave the company a “buy” rating in a research note on Wednesday, December 17th. Finally, Needham & Company LLC boosted their target price on SiBone from $24.00 to $27.00 and gave the stock a “buy” rating in a report on Tuesday, December 16th. Five analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $25.00.

Institutional Investors Weigh In On SiBone

Several institutional investors and hedge funds have recently modified their holdings of the stock. Tudor Investment Corp ET AL boosted its holdings in SiBone by 0.8% in the 3rd quarter. Tudor Investment Corp ET AL now owns 258,032 shares of the company’s stock worth $3,798,000 after acquiring an additional 1,968 shares during the period. PharVision Advisers LLC purchased a new stake in SiBone during the 3rd quarter worth $431,000. XTX Topco Ltd grew its stake in shares of SiBone by 70.9% during the third quarter. XTX Topco Ltd now owns 33,870 shares of the company’s stock valued at $499,000 after acquiring an additional 14,053 shares in the last quarter. Virtus Advisers LLC increased its position in shares of SiBone by 174.3% during the third quarter. Virtus Advisers LLC now owns 11,333 shares of the company’s stock worth $167,000 after acquiring an additional 7,201 shares during the last quarter. Finally, Quarry LP grew its position in shares of SiBone by 862.6% during the third quarter. Quarry LP now owns 4,861 shares of the company’s stock worth $72,000 after buying an additional 4,356 shares in the last quarter. Hedge funds and other institutional investors own 98.11% of the company’s stock.

About SiBone

Si-BONE, Inc is a commercial?stage medical device company focused on the design, development and commercialization of implant systems to treat degenerative conditions of the sacroiliac (SI) joint. Its flagship product, the iFuse Implant System, consists of triangular titanium implants that are inserted via a minimally invasive surgical procedure to stabilize the SI joint and alleviate chronic lower back and buttock pain.

FDA?cleared in 2012, the iFuse portfolio has expanded to include the iFuse-3D and iFuse-3Di devices, which feature a porous, 3D-printed surface to promote bone ongrowth and biological fixation.